慢性心力衰竭与抑郁症共同发病机制及药物治疗的研究进展

慢性心力衰竭（CHF）和抑郁症的共病率为10%~79%，二者的发病机制均涉及免疫炎症系统激活、胰岛素抵抗、肠道菌群失调等方面，而其机制的调节亦是双向的、复杂的。现有的诊疗指南及临床实践中尚缺乏对二者同时有效的药物，但有近期报道部分药物如沙库巴曲缬沙坦、新型抗抑郁药、参松养心胶囊和芪苈强心胶囊、肠道菌群调节剂等对二者均有一定的治疗作用。本文将对二者的共同发病机制及药物治疗的研究进展进行综述，为CHF和抑郁症共病的临床诊断及治疗提供新的思路和依据。

Advances in Mechanism of Coexistence and Pharmaceutical Treatment of Chronic Heart Failure and Depression

The coprevalence of chronic heart failure(CHF)and depression is 10%-79%,the pathogenesis of these two diseases is related to the activation of immune inflammatory system,insulin resistance and intestinal flora imbalance,and relevant regulation is bidirectional and complex.There is a lack of efficient drugs for both CHF and depression recommended by available diagnosis and treatment guidelines and present clinical practice.But it has recently been reported that some drugs(sacubitril/valsartan,new antidepressants,shensongyangxin and qiliqiangxin capsules,regulators of the intestinal flora)may be partially effective for CHF with depression.We reviewed the mechanism of coexistence and pharmaceutical treatment of CHF and depression,providing new ideas and evidence for clinical diagnosis and treatment of CHF and depression.